Acute Myeloid Leukemia Market Snapshot
| Study Period: | 2019-2027 |
| Base Year: | 2021 |
| Fastest Growing Market: | Asia Pacific |
| Largest Market: | North America |
| CAGR: | 10.88 % |
|
Need a report that reflects how COVID-19 has impacted this market and its growth?
Market Overview
The acute myeloid leukemia market was valued at USD 1,355.58 million in 2021, and it is expected to record a CAGR of 10.88% over the forecast period, 2022-2027.
The COVID-19 pandemic has had a significant impact on the acute myeloid leukemia drugs market. According to the study published in Springer Nature Limited, titled ‘Impact of Covid-19 on the treatment of acute myeloid leukemia’ in June 2020, induction chemotherapy and high-dose consolidation chemotherapy cause severe and protracted granulocytopenia in patients with acute myeloid leukemia (AML), as well as an increased risk of serious infections. The increase in vulnerability of AML patients for COVID-19 might have expected to decline the market growth during the pandemic.
The key factors propelling the growth of this market are the high incidence and prevalence of acute myeloid leukemia, advancements in pharmacology and molecular biology to promote drug development, and increasing investments in research and development by pharmaceutical companies.
According to the American Cancer Society, it is estimated that there will be 60,650 new leukemia cancer cases, of which 24,000 are expected to die in 2022 in the United States. In addition to this, according to the same source, 20,050 new cases of acute myeloid leukemia (AML) are estimated in 2022, with estimated deaths of 11,540 in the United States. This will lead to increase adoption of AML therapies. The rising prevalence of AML in developed countries such as the United States is expected to drive this market's growth.
Furthermore, with the rising investment in research and development, there is an increasing number of clinical trials conducted to demonstrate the effectiveness of the drugs. This is expected to drive the market over the forecast period. For Instance, as per the United States National Library of Medicine, a study titled ‘Daunorubicin or Idarubicin With Cytarabine Plus Quizartinib vs. Physician's Choice in Newly Diagnosed FLT3-ITD+ AML (Q-SOC)’ is in Phase III of clinical trials, and the study was estimated to start in November 2021 and complete in March 2025.
In addition, the global rise in the incidence of AML, along with increased mortality due to the disease, is expected to create a huge demand for AML therapeutics, thus, augmenting the global AML market. On the other hand, complications related to chemotherapy and stringent regulations on drug approvals are the factors that are expected to hinder market growth.
Scope of the Report
As per the scope of this report, acute myeloid leukemia is also known as acute myelogenous leukemia, acute myeloblastic leukemia, acute granulocytic leukemia, or acute non-lymphocytic leukemia. In acute myeloid leukemia, there is a rapid production of abnormal white blood cells that get collected in the bone marrow and disturb the production of normal blood cells. The acute myeloid leukemia market is segmented by chemotherapy (cytarabine, anthracycline drugs, alkylating agents, anti-metabolites, tyrosine kinase inhibitors, hormonal therapy, and other chemotherapies) and geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.
| Chemotherapy | |
| Cytarabine | |
| Anthracycline Drugs | |
| Alkylating Agents | |
| Anti-metabolites | |
| Tyrosine Kinase Inhibitors | |
| Hormonal Therapy | |
| Other Chemotherapies |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Key Market Trends
Cytarabine is Expected to Hold a Significant Market Share in the Chemotherapy Segment
In the chemotherapy segment of the acute myeloid leukemia market, cytarabine is believed to have a significant market size. It is expected to grow at a larger pace during the forecast period.
Cytarabine is used to treat different forms of leukemia, including acute and chronic myelogenous leukemia (AML and CML), acute lymphocytic leukemia (ALL), and acute promyelocytic leukemia (APL). It is also used to treat Hodgkin's lymphoma, meningeal leukemia, and other types of lymphoma (cancers found in the linings of the brain and spinal cord). Due to its effectiveness in the treatment of acute myeloid leukemia, cytarabine is being widely used during chemotherapy. Organizations that are working for cancer, such as Macmillan Cancer Support, have stated that cytarabine is more effective for acute myeloid leukemia, which is why the drug is used widely; therefore, this sub-segment is expected to have a large market share in the chemotherapy segment.
Rising approvals for Cytarabine by the US Food and Drug Administration for the treatment of acute myeloid leukemia are also expected to drive the growth of this market. For Instance, in March 2021, Jazz Pharmaceuticals PLC received a US Food and Drug Administration (FDA) approval for a revised label for Vyxeos (daunorubicin and cytarabine) to include a new indication to treat newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in pediatric patients aged one year and older. Furthermore, in October 2020, AbbVie Inc. and Genentech Inc received Food and Drug Administration approval for Venclexta, which is a combination of venetoclax with azacitidine, decitabine, or low-dose cytarabine (LDAC) for newly-diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities precluding intensive induction chemotherapy. These approvals from the regulatory authorities are driving the growth of the market.
Therefore, owing to the above-mentioned factors, the cytarabine segment is expected to show a significant share during the forecast period.
To understand key trends, Download Sample Report
North America Holds a Major Share and Expected to do Same during the Forecast Period
North America currently dominates the market for acute myeloid leukemia and is expected to continue its stronghold over the forecast period. The rising prevalence of acute myeloid leukemia cases in the United States is expected to drive the growth of this market in this region. For instance, according to the American Society of Clinical Oncology in 2021, acute myeloid leukemia is a rare malignancy that accounts for around 1% of all cancers. In the United States, an estimated 20,240 people of all ages (11,230 men and boys and 9,010 women and girls) were diagnosed with this disease in 2021. AML is the second most prevalent kind of leukemia in adults and children, with adults accounting for the majority of occurrences. Therefore, the rising prevalence of acute myeloid leukemia in the United States will lead to higher adoption of therapy for this disease, thereby expected to drive the growth of this market in North America.
Furthermore, rising research and development and product launches for acute myeloid leukemia are further expected to drive the market growth in this region. For instance, in September 2020, Bristol Myers Squibb received the US Food and Drug Administration approval for Onureg (azacitidine 300 mg tablets) for the continued treatment of adult patients with AML who are not able to complete intensive curative therapy.
Therefore, owing to the aforementioned factors, the market is expected to show a major share in North America.
To understand geography trends, Download Sample Report
Competitive Landscape
The acute myeloid leukemia market is moderately competitive and consists of several major players. In terms of market share, few major players currently dominate the market. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new techniques with good results. The major players in this market include Novartis AG, Teva Pharmaceuticals, Pfizer, Bristol Myer Squibb, and Sanofi-Aventis (Genzyme Corporation).
Recent Developments
- In January 2022, the US Food and Drug Administration (FDA) granted the company orphan drug designation for its pipeline compound OM-301 to treat acute myeloid leukemia (AML) developed by Oncolyze Inc.
- In December 2021, the European Commission granted Orphan Drug Designation to SNDX-5613, a highly selective oral menin inhibitor, to treat acute myeloid leukemia (AML) developed by Syndax Pharmaceuticals Inc.
Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Incidence and Prevalence of Acute Myeloid Leukemia
4.2.2 Advancement in Pharmacology and Molecular Biology to Promote Drug Development
4.2.3 Increasing Investments in Research and Development
4.3 Market Restraints
4.3.1 Stringent Regulations on Drugs
4.3.2 Complications Related to Chemotherapy
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 Chemotherapy
5.1.1 Cytarabine
5.1.2 Anthracycline Drugs
5.1.3 Alkylating Agents
5.1.4 Anti-metabolites
5.1.5 Tyrosine Kinase Inhibitors
5.1.6 Hormonal Therapy
5.1.7 Other Chemotherapies
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East & Africa
5.2.4.1 GCC
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East & Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Bristol-Myers Squibb Company (Celgene Corporation)
6.1.2 Novartis AG
6.1.3 Genmab AS
6.1.4 Otsuka Holdings Co. Ltd
6.1.5 Sanofi-Aventis (Genzyme Corporation)
6.1.6 Teva Pharmaceutical (Cephalon Inc.)
6.1.7 Pfizer Inc.
6.1.8 F. Hoffmann-La Roche Ltd
6.1.9 Sunesis Pharmaceuticals Inc.
6.1.10 Astellas Pharma
6.1.11 Oncolyze Inc.
6.1.12 Syndax Pharmaceuticals Inc.
6.1.13 AbbVie Inc.
6.1.14 Amgen Inc.
6.1.15 Agios Pharmaceuticals Inc.
*List Not Exhaustive7. MARKET OPPORTUNITIES AND FUTURE TRENDS
You can also purchase parts of this report. Do you want to check out a section wise price list?
Frequently Asked Questions
What is the study period of this market?
The Acute Myeloid Leukemia Market market is studied from 2019 - 2027.
What is the growth rate of Acute Myeloid Leukemia Market?
The Acute Myeloid Leukemia Market is growing at a CAGR of 10.88% over the next 5 years.
Which region has highest growth rate in Acute Myeloid Leukemia Market?
Asia Pacific is growing at the highest CAGR over 2021- 2026.
Which region has largest share in Acute Myeloid Leukemia Market?
North America holds highest share in 2021.
Who are the key players in Acute Myeloid Leukemia Market?
Pfizer Inc., Novartis AG, Sanofi-Aventis (Genzyme Corporation), Otsuka holdings co., ltd., Bristol Myers Squibb are the major companies operating in Acute Myeloid Leukemia Market.
